English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 16 April 2024, 17:04 HKT/SGT
Share:
    

Source: Autonomix Medical Inc.
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

NEW YORK, Apr 16, 2024 - (ACN Newswire) - A new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders, has been published by Benzinga. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.

The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related disorders. By targeting the root causes associated with the PNS, rather than just managing symptoms, Autonomix Medical's technology offers a novel solution that combines both detection and ablation of problematic nerves in a single procedure. This approach, likened to a "GPS" for nerve treatment, allows for precise identification and treatment of the nerves involved, enhancing the accuracy and effectiveness of procedures.

In a notable application, the company is focusing its efforts on managing pancreatic cancer pain — a condition notoriously difficult to treat due to its proximity to critical nerves. The technology's high sensitivity in detecting neural signals—up to 3,000 times greater than existing technologies — promises not only to improve outcomes in pain management but also to significantly reduce the need for opioids, addressing a major public health challenge.

This exposure in Benzinga underscores the potential of Autonomix Medical's technology to transform the field of electrophysiology and pain management, potentially tapping into a market exceeding $100 billion. As the company progresses with its clinical trials, the successful implementation of its technology could revolutionize treatment approaches for a wide range of diseases, offering hope to millions of patients worldwide.

To read the full article, click here.

More Pancreatic Cancer News:

  • Candel Therapeutics, Inc. ((Nasdaq: CADL) announced that the FDA has granted Orphan Drug Designation to their advanced biological immunotherapy, CAN-2409, for treating pancreatic cancer, following promising phase 2 clinical trial results that more than doubled median overall survival when added to standard care.
  • RenovoRx, Inc. (Nasdaq: RNXT) announced an $11.1 million private placement, extending their financial runway into 2026, which will support the continuation and completion of their pivotal Phase III TIGeR-PaC clinical trial for pancreatic cancer. This funding also facilitates the expansion of their Trans-Arterial Micro-Perfusion (TAMP) clinical development pipeline into additional cancer indications.

Note: The details provided in this press release are based on information featured in the Benzinga article and do not constitute forward-looking statements.

For more information, contact:
Plato Data Intelligence
144 E44th St
New York NY 10017
PlatoAiStream.com
Zephyr@platodata.io

 



Topic: Press release summary
Source: Autonomix Medical Inc.

Sectors: Healthcare & Pharm, MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Hitachi High-Tech Launches the SU3900SE and SU3800SE Series High-Resolution Schottky Field Emission Scanning Electron Microscopes Allowing Observation of Large and Heavy Samples at the Nano Level  
Tuesday, May 28, 2024 8:30:00 PM
Celonis and NEC begin Proof of Concept Integrating Generative AI and Process Intelligence  
Tuesday, May 28, 2024 7:20:00 PM
Genetec's Consistent Performance Delivers Higher Overall Margins in Q4FY2024  
May 28, 2024 19:18 HKT/SGT
Fourth Paradigm Announces Business Performance For The First Quarter Ended March 31 2024  
May 28, 2024 18:00 HKT/SGT
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project  
May 28, 2024 18:00 HKT/SGT
MUFG Pension & Market Services Inaugurates Hong Kong Office, Sets the Stage for Expansion into the Region's Pension Market  
May 28, 2024 16:35 HKT/SGT
CR Pharmaceutical Armed with Leading Advantages Releases Growth Potential and Achieves High-quality Sustainable Development  
May 28, 2024 16:28 HKT/SGT
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea  
Tuesday, May 28, 2024 2:19:00 PM
Fosun Sells German Private Bank HAL and Retains HAFS Asset Servicing Business, Aligns with its Asset-Light Strategy  
May 28, 2024 13:47 HKT/SGT
Alta Partners with Davidson Kempner to Enhance Investor Access to Multi-Strategy and Asset-Based Lending Strategies  
May 28, 2024 12:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575